Expression and Characterization of Functional Recombinant Bet v 1.0101 in the Chloroplast of Chlamydomonas reinhardtii

Immunotherapy using algal-produced Ara h 1 core domain suppresses peanut allergy in mice

(2016) James A. Gregory et al.   PLANT BIOTECHNOLOGY JOURNAL

Mechanisms of allergen-specific immunotherapy: Multiple suppressor factors at work in immune tolerance to allergens

(2014) Mübeccel Akdis et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Photosynthetic biomanufacturing in green algae; production of recombinant proteins for industrial, nutritional, and medical uses

(2014) Beth A. Rasala et al.   PHOTOSYNTHESIS RESEARCH

Molecular Approach to Allergy Diagnosis and Therapy

(2014) Fatima Ferreira et al.   YONSEI MEDICAL JOURNAL

Production of therapeutic proteins in the chloroplast of Chlamydomonas reinhardtii

(2014) Alma Lorena Almaraz-Delgado et al.   AMB Express

Future directions for the development ofChlamydomonas-based vaccines

(2013) Sergio Rosales-Mendoza   Expert Review of Vaccines

Analysis of the landscape of biologically-derived pharmaceuticals in Europe: Dominant production systems, molecule types on the rise and approval trends

(2012) Sarantos Kyriakopoulos et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Reshaping the Bet v 1 fold modulates TH polarization

(2011) Michael Wallner et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Enhanced chloroplast transgene expression in a nuclear mutant of Chlamydomonas

(2010) Laure Michelet et al.   PLANT BIOTECHNOLOGY JOURNAL

Standardization of allergen products: 1. Detailed characterization of GMP-produced recombinant Bet v 1.0101 as biological reference preparation

(2009) M. Himly et al.   ALLERGY